Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T85943 Target Info
Target Name Proto-oncogene c-Src (SRC)
Synonyms pp60c-src; Tyrosine kinase (pp60(src)); Src tyrosine kinase; SRC1; Proto-oncogene tyrosine-protein kinase Src; Pp60(src); P60-Src; C-src TK; C-Src
Target Type Successful Target
Gene Name SRC
Biochemical Class Kinase
UniProt ID
SRC_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2011101806
Title Bicyclic Compounds and Their Uses As Dual C-Src / Jak Inhibitors.
Abstract The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.
Applicant(s) Debiopharm Sa
Representative Drug(s) D0M5AG Drug Info IC50 = 1 nM Click to Show More [1]
2 D09RTW Drug Info IC50 = 2 nM [1]
3 D0M9YZ Drug Info IC50 = 2 nM [1]
4 D0Q5JV Drug Info IC50 = 5 nM [1]
5 D0QD5Y Drug Info IC50 = 10 nM [1]
6 D0VI7E Drug Info IC50 = 27 nM [1]
United States Patent and Trademark Office (USPTO)
Patent ID US9029386
Title Inhibitors of Kinase Activity.
Applicant(s) Ym Biosciences Australia Pty
Representative Drug(s) D0AK1F Drug Info N.A. [2]
Patent ID US20130137660
Title Inhibitors of Kinase Activity.
Applicant(s) Ym Biosciences Australia Pty
Representative Drug(s) D0AK1F Drug Info N.A. [2]
References  Top
REF 1 A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
REF 2 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.